This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk's Semaglutide Shows Remarkable Results in Study
by Zacks Equity Research
Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
by Zacks Equity Research
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.
The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global
Top Research Reports for Eli Lilly, Halliburton & Monster Beverage
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LILY), Halliburton (HAL), and Monster Beverage (MNST).
Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
Q2 Earnings Fail to Impress Pharma ETF
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs.
Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss in the second quarter due to an increase in general and administrative expenses.
Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY
by Zacks Equity Research
The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.
AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact
by Zacks Equity Research
AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.
Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View
by Zacks Equity Research
Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.
Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK
by Zacks Equity Research
Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
by Arpita Dutt
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?
3 Buy-Ranked Stocks That Just Crushed Earnings
by Jeffrey Hymen
These earnings reports not only demonstrate the past quarter???s solid performance, but they also preview its financial outlook over its next operational quarter.
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK
by Zacks Equity Research
We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Lilly (LLY) Tops Q2 Earnings & Sales, Ups View, Stock Falls
by Zacks Equity Research
Lilly beat estimates for both sales and earnings and raised its 2017 outlook. However, it said the NDA resubmission for its rheumatoid arthritis drug baricitinib will not occur this year.
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
Merck's Biosimilar Insulin Gets Tentative FDA Approval
by Zacks Equity Research
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Why Did Radius Health (RDUS) Stock Plummet Today?
by Ryan McQueeney
Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.
Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?
by Zacks Equity Research
On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN).
Lilly Settles Patent Litigation on Cialis with Generic Firms
by Zacks Equity Research
Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).
5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.